Bioventus Inc. (NYSE:BVS) CFO Sells $113,018.49 in Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 10,733 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $10.53, for a total value of $113,018.49. Following the completion of the sale, the chief financial officer now owns 105,162 shares in the company, valued at $1,107,355.86. The trade was a 9.26 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Bioventus Trading Down 3.5 %

Shares of NYSE:BVS opened at $10.62 on Friday. The business’s 50 day moving average price is $11.81 and its 200-day moving average price is $9.80. Bioventus Inc. has a 1 year low of $3.90 and a 1 year high of $14.38. The firm has a market capitalization of $861.87 million, a price-to-earnings ratio of -17.41 and a beta of 0.79. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99.

Bioventus (NYSE:BVS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. The business had revenue of $138.96 million for the quarter, compared to the consensus estimate of $132.57 million. Bioventus had a negative net margin of 7.11% and a positive return on equity of 15.61%. During the same period last year, the firm posted $0.05 earnings per share. On average, equities research analysts forecast that Bioventus Inc. will post 0.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BVS has been the topic of several recent research reports. Canaccord Genuity Group raised their price objective on shares of Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Craig Hallum lifted their price objective on shares of Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a report on Friday, September 27th. Finally, JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and increased their target price for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Institutional Investors Weigh In On Bioventus

Institutional investors have recently bought and sold shares of the company. Royce & Associates LP acquired a new stake in shares of Bioventus in the third quarter worth approximately $8,337,000. Renaissance Technologies LLC boosted its stake in Bioventus by 401.5% during the 2nd quarter. Renaissance Technologies LLC now owns 503,175 shares of the company’s stock worth $2,893,000 after purchasing an additional 402,841 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of Bioventus during the third quarter worth $4,515,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Bioventus in the third quarter valued at about $3,092,000. Finally, State Street Corp raised its position in shares of Bioventus by 38.8% in the third quarter. State Street Corp now owns 676,501 shares of the company’s stock valued at $8,084,000 after buying an additional 189,216 shares during the last quarter. 62.94% of the stock is currently owned by institutional investors and hedge funds.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.